Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

806544

registered interest
date	14/12/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Chronic Illnesses: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the potential effect of the use of (a) the drug Orkambi and (b) other new medicines for long-term conditions on (i) the budget of the NHS and (ii) resources available for hospital inpatients.
tabling member constituency	Hemel Hempstead
tabling member printed	Sir Mike Penning
uin	119620
answer	answer is ministerial correction date of answer 21/12/2017 answer text <p>The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care. Through its technology appraisal programme, NICE provides authoritative, evidence-based guidance for the National Health Service on whether drugs and other treatments represent a clinically and cost effective use of resources. NHS organisations are legally required to make funding available for drugs and treatments recommended in NICE technology appraisal guidance.</p><p> </p><p>NICE has recommended a number of drugs for the treatment of long-term conditions and has published resource impact tools alongside its recommendations to aid NHS organisations in assessing the expected impact of NICE’s recommendations. NICE published technology appraisal guidance in July 2016 that does not recommend Orkambi as a clinically and cost effective use of NHS resources</p><p> </p><p>There has been a constructive dialogue between the company, NHS England and NICE, including discussion hosted through NICE’s confidential ‘Office for Market Access’, although NICE is yet to receive any fresh proposals from Vertex, the company that manufactures Orkambi. Both NHS England and NICE have been consistent in advice to Vertex, that progress can only be made by working through NICE’s appraisal processes and the existing commercial framework.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 21/12/2017 17:44:44 answering member 4067 label Biography information for Steve Brine
tabling member	1528 label Biography information for Sir Mike Penning

781421

registered interest
date	31/10/2017
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Chronic Illnesses: Medical Treatments
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, with reference to the proposals contained in the NHS England consultation entitled, Items which should not be routinely prescribed in primary care: A Consultation on guidance of CCGs, what assessment his Department has made of the potential effect of those proposals on the medicine-taking behaviour of patients who rely on regular and multiple medications to prevent symptoms of long-term conditions.
tabling member constituency	Birmingham, Selly Oak
tabling member printed	Steve McCabe
uin	110622
answer	answer is ministerial correction date of answer 03/11/2017 answer text <p>NHS England’s consultation on draft guidance for clinical commissioning groups on a range of items that should not routinely be prescribed in primary care ended on 21 October. The draft guidance seeks to ensure that the National Health Service is able to secure best value from its use of medicines and therefore focuses on areas of prescribing that have been found to be ineffective or where there are more cost effective alternatives. A full Equality Impact Assessment was published alongside the draft guidance and a further Assessment will be published when final guidance is produced.</p><p> </p><p>We would not want to pre-empt any outcome following NHS England’s analysis of the responses it has received. However, we are assured that as part of issuing the final guidance, careful consideration will be given by NHS England to the responses to the consultation, both to ensure that particular groups of people are not disproportionately affected and that principles of best practice on clinical prescribing are adhered to.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 110618 110619 110620 110621 question first answered 03/11/2017 14:35:15 answering member 4067 label Biography information for Steve Brine
tabling member	298 label Biography information for Steve McCabe